We source drug assets in the early stages of preclinical and clinical development, and assume full responsibility for value creation through further development. We have expertise in small molecules as well as biologics across most therapeutic areas, and prefer to acquire drug assets in early stages of clinical development in order to advance them to proof-of-concept and exit. Investing early combined with our de-risking capabilities creates the opportunity for superior returns earlier.

We are a private equity fund developing a diversified, risk-adjusted portfolio of novel drug assets. We bring integral drug development expertise, capital and operational efficiencies to each of our investments. Our private equity fund structure represents the most viable and scalable approach to financing our drug development efforts and to attaining superior returns on investment.

We partner with the innovators of promising early-stage assets. Applying our financial resources and drug development expertise, we work alongside our partners to rapidly advance their products through development cycles using creative, proven financial and program structures. Together, we seek to build significant value around the asset opportunity and share equitably in the success of our endeavors.